Key Takeaways
- • Four clinical and exploration-stage companies plan to raise approximately $652 million in the week ahead, with biotechs dominating the slate: Seaport Therapeutics ($201M at $976M valuation), Avalyn Pharma ($201M at $683M valuation), Hemab Therapeutics ($200M at $715M valuation), and Silver Bow Mining ($50M at $358M valuation).
- • Seaport Therapeutics targets neuropsychiatric disorders with GlyphAllo in Phase 2b for major depressive disorder and GlyphAgo in Phase 1 for generalized anxiety disorder, positioning the company in a high-demand therapeutic category.
- • Avalyn Pharma's pulmonary fibrosis program includes two late-stage candidates (AP01 and AP02) with topline data expected in mid-to-late 2027, representing a longer clinical timeline but addressing a significant unmet medical need in rare respiratory disease.
- • Hemab Therapeutics brings advanced coagulation disorder therapies with its lead candidate sutacimig already cleared for Phase 3 in Glanzmann thrombasthenia, offering a more de-risked development profile than earlier-stage competitors.
- • Bill Ackman's Pershing Square (PS) and Pershing Square USA (PSUS) closed-end fund offerings are concurrent with the biotech and mining IPOs, with Pershing Square Inc. planning to offer up to 33.12 million shares at $50 per share, positioning the week as a significant capital formation event across alternative asset classes.
Summary
The U.S. IPO calendar for the week of April 24–27, 2026 features a concentrated slate of four clinical-stage and exploration-stage companies alongside marquee structured fund offerings from activist investor Bill Ackman. The biotech sector dominates both volume and capital raised, reflecting sustained institutional appetite for therapies addressing underserved patient populations despite persistent valuation scrutiny in the life sciences space.
Seaport Therapeutics and Avalyn Pharma each plan to raise $201 million, anchoring the biotech offerings. Seaport is developing neuropsychiatric therapeutics with GlyphAllo in Phase 2b evaluation for major depressive disorder and GlyphAgo in Phase 1 for generalized anxiety disorder, alongside additional preclinical CNS-focused candidates. The company's $976 million implied post-money valuation reflects investor confidence in the substantial addressable market for depression and anxiety therapies. Avalyn Pharma, valued at $683 million, is clinical-stage focused on inhaled antifibrotic therapies for rare respiratory diseases, particularly pulmonary fibrosis. Its two most advanced programs—AP01 in Phase 2b for progressive pulmonary fibrosis and AP02 in Phase 2 for idiopathic pulmonary fibrosis—carry a notable timeline risk, with topline data not expected until mid-to-late 2027.
Hemab Therapeutics ($715 million valuation, $200 million raise) takes a more de-risked approach with sutacimig (HMB-001), an antibody-based coagulation therapy that has completed Phase 2 and is positioned for Phase 3 advancement in Glanzmann thrombasthenia, with parallel Phase 2 evaluation in Factor VII deficiency. This advancement represents meaningful clinical progress relative to earlier-stage competitors.
Silver Bow Mining, an exploration-stage precious and base metals company, rounds out the traditional IPO calendar with a $50 million raise at $358 million valuation. The company owns 3,347 acres of patented mineral claims in Silver Bow County, Montana, and has yet to generate revenue, positioning it as a speculative play on silver, zinc, gold, lead, and copper exposure.
Concurrent with these offerings, Bill Ackman's Pershing Square Inc. (PS) and Pershing Square USA (PSUS) are launching their own capital raises, with Pershing Square Inc. planning to offer up to 33.12 million shares at $50 per share. These closed-end fund structures represent an alternative deployment vehicle for institutional capital, reflecting Ackman's ongoing capital formation strategy in the alternative asset management space.
Seaport Therapeutics and Avalyn Pharma each plan to raise $201 million, anchoring the biotech offerings. Seaport is developing neuropsychiatric therapeutics with GlyphAllo in Phase 2b evaluation for major depressive disorder and GlyphAgo in Phase 1 for generalized anxiety disorder, alongside additional preclinical CNS-focused candidates. The company's $976 million implied post-money valuation reflects investor confidence in the substantial addressable market for depression and anxiety therapies. Avalyn Pharma, valued at $683 million, is clinical-stage focused on inhaled antifibrotic therapies for rare respiratory diseases, particularly pulmonary fibrosis. Its two most advanced programs—AP01 in Phase 2b for progressive pulmonary fibrosis and AP02 in Phase 2 for idiopathic pulmonary fibrosis—carry a notable timeline risk, with topline data not expected until mid-to-late 2027.
Hemab Therapeutics ($715 million valuation, $200 million raise) takes a more de-risked approach with sutacimig (HMB-001), an antibody-based coagulation therapy that has completed Phase 2 and is positioned for Phase 3 advancement in Glanzmann thrombasthenia, with parallel Phase 2 evaluation in Factor VII deficiency. This advancement represents meaningful clinical progress relative to earlier-stage competitors.
Silver Bow Mining, an exploration-stage precious and base metals company, rounds out the traditional IPO calendar with a $50 million raise at $358 million valuation. The company owns 3,347 acres of patented mineral claims in Silver Bow County, Montana, and has yet to generate revenue, positioning it as a speculative play on silver, zinc, gold, lead, and copper exposure.
Concurrent with these offerings, Bill Ackman's Pershing Square Inc. (PS) and Pershing Square USA (PSUS) are launching their own capital raises, with Pershing Square Inc. planning to offer up to 33.12 million shares at $50 per share. These closed-end fund structures represent an alternative deployment vehicle for institutional capital, reflecting Ackman's ongoing capital formation strategy in the alternative asset management space.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.